UPDATE: Bank of America Reiterates Neutral Rating, Raises PT on Idenix Pharmaceuticals
In a report published Monday, Bank of America reiterated its Neutral rating on Idenix Pharmaceuticals (NASDAQ: IDIX ), and slightly raised its price target from $6.00 to $7.00. Bank of America noted, “Today IDIX announced a non-exclusive collaboration with JNJ to initiate Phase 2 all-oral combination studies for the treatment
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here